TSHA
Taysha Gene Therapies Inc.
Company Overview
| Mkt Cap | $1.06B | Price | $4.19 |
| Volume | 4.39M | Change | +5.01% |
| P/E Ratio | -11.9 | Open | $3.99 |
| Revenue | $8.3M | Prev Close | $3.99 |
| Net Income | $-89.3M | 52W Range | $1.05 - $5.51 |
| Div Yield | N/A | Target | $10.08 |
| Overall | 50 | Value | 55 |
| Quality | -- | Technical | 45 |
No chart data available
About Taysha Gene Therapies Inc.
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Latest News
Cantor Fitzgerald Keeps Their Buy Rating on Taysha Gene Therapies (TSHA)
Piper Sandler Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA)
Taysha Gene Therapies (TSHA) Receives a Rating Update from a Top Analyst
Analysts Offer Insights on Healthcare Companies: Taysha Gene Therapies (TSHA) and Day One Biopharmaceuticals (DAWN)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TSHA | $4.19 | +5.0% | 4.39M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Taysha Gene Therapies Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW